Novavax Inc vs Under Armour Inc Class A — how do they compare? Novavax Inc trades at $7.93 (market cap $1.31B), while Under Armour Inc Class A trades at $5.2 (market cap $2.26B). The key difference: Under Armour Inc Class A is the larger of the two by market cap. Which is the better fit depends on your goals.
| NVAX | UA | |
|---|---|---|
Market Cap | $1.31B | $2.26B |
Sector | Health | Consumer Cyclical |
52-Week High | $11.19 | $7.88 |
52-Week Low | $6.22 | $3.96 |
Enterprise Value | $889.30M | $3.24B |
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $7.89, down 0.75% on the day, with a bullish technical signal despite mixed indicators. The company reported a strong Q2 2026 earnings beat, raising its full-year revenue outlook, while maintaining a low valuation with a P/E of 3.14 and EV/EBITDA of 1.72. However, negative net income margin and shareholder equity highlight financial challenges.
The outlook is cautiously optimistic, driven by partnership milestones with Sanofi and cost reductions, but risks include persistent cash burn and competitive vaccine market pressures. Analyst consensus leans bullish with 74% buy ratings, suggesting potential upside if execution improves.
No Aura AI signal available yet.
Trailing returns across standard periods
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →